Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
12:12pm, Monday, 12'th Aug 2024
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stre
COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript
01:22am, Sunday, 04'th Aug 2024
COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri
Compass Pathways announces second quarter 2024 financial results and business highlights
06:30am, Thursday, 01'st Aug 2024
LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in men
Compass Pathways to announce second quarter financial results on August 1, 2024
07:01am, Wednesday, 24'th Jul 2024
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
10:11am, Monday, 08'th Jul 2024
COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies. CO
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
07:45am, Monday, 08'th Jul 2024
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketam
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
03:43pm, Tuesday, 02'nd Jul 2024
While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybi
Compass Pathways appoints Lori Englebert as Chief Commercial Officer
06:30am, Wednesday, 26'th Jun 2024
LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, t
Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
04:01pm, Monday, 24'th Jun 2024
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
Should You Buy the Dip on Compass Pathways Stock?
06:25am, Wednesday, 12'th Jun 2024
Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators.
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
12:15pm, Thursday, 23'rd May 2024
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
08:05am, Tuesday, 21'st May 2024
Compass Pathways will report some key data in Q4. One of its competitors will soon face a critical interaction with regulators.
COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript
05:31pm, Saturday, 11'th May 2024
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2024 Results Conference Call May 8, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxa
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
06:45am, Wednesday, 08'th May 2024
LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental he
LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, to
